Compare GSM & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSM | ZVRA |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.2M | 562.2M |
| IPO Year | 2015 | 2015 |
| Metric | GSM | ZVRA |
|---|---|---|
| Price | $4.47 | $11.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $23.36 | $37.27 |
| Revenue Next Year | $17.85 | $53.42 |
| P/E Ratio | ★ N/A | $15.32 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $3.08 | $7.16 |
| 52 Week High | $5.74 | $15.04 |
| Indicator | GSM | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 72.53 | 49.91 |
| Support Level | $4.46 | $8.26 |
| Resistance Level | $4.71 | $12.06 |
| Average True Range (ATR) | 0.20 | 0.51 |
| MACD | 0.16 | 0.17 |
| Stochastic Oscillator | 86.31 | 72.98 |
Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's operating segments include Canada - Silicon Metals, Canada - Silicon Alloys, U.S. - Silicon Metals, U.S. - Silicon Alloys, Europe - Manganese Alloys, Europe - Silicon Metals, Europe - Silicon Alloys, South Africa - Silicon Metals, South Africa - Silicon Alloys, and Other segments. The primary raw materials the company uses to produce its electrometallurgy products include its coal and quartz mining operations and its silicon metal and ferroalloy production. The firm generates key revenue from Silicon metal and Manganese-based alloys.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.